Although combination treatment with dabrafenib and trametinib is an approved therapy for BRAF mutant non-small cell lung cancer, the prevalence of BRAF mutations in this group is only 3% to 5%.27 This evidence concerns the gene BRAF and non-small cell lung carcinoma.